BIOAVAILABILITY AND ACCEPTABILITY OF A DISPERSIBLE FORMULATION OF LEVODOPA-BENSERAZIDE IN PARKINSONIAN-PATIENTS WITH AND WITHOUT DYSPHAGIA

被引：25
|
作者：
BAYER, AJ
DAY, JJ
FINUCANE, P
PATHY, MSJ
机构：
来源：
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | 1988年 / 13卷 / 03期
关键词：
D O I：
10.1111/j.1365-2710.1988.tb00179.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：191 / 194
页数：4
相关论文
共 50 条
  • [31] DREAM-RECALL AND DREAM CONTENT IN LEVODOPA-TREATED PARKINSONIAN-PATIENTS
    MASSETANI, R
    LUCCHETTI, R
    PICCINI, P
    BIANCHI, F
    MAESTRINI, M
    MURATORIO, A
    RESEARCH COMMUNICATIONS IN PSYCHOLOGY PSYCHIATRY AND BEHAVIOR, 1986, 11 (2-3): : 65 - 73
  • [32] CONTINUOUS SUBCUTANEOUS APOMORPHINE AS REPLACEMENT FOR LEVODOPA IN SEVERE PARKINSONIAN-PATIENTS AFTER SURGERY
    BROUSSOLLE, E
    MARION, MH
    POLLAK, P
    LANCET, 1992, 340 (8823) : 859 - 860
  • [33] EVOLUTION OF SPEECH DISORDERS IN PARKINSONIAN-PATIENTS PRESENTING LONG-TERM LEVODOPA SYNDROMES
    BORROMEI, A
    PHARMACOLOGY, 1982, 24 (02) : 136 - 137
  • [34] COMBINATION OF SELEGILINE AND CONTROLLED RELEASE LEVODOPA IN THE TREATMENT OF FLUCTUATIONS OF CLINICAL DISABILITY IN PARKINSONIAN-PATIENTS
    CHOUZA, C
    ALJANATI, R
    SCARAMELLI, A
    DEMEDINA, O
    CAAMANO, JL
    BUZO, R
    FERNANDEZ, A
    ROMERO, S
    ACTA NEUROLOGICA SCANDINAVICA, 1989, 80 : 127 - 137
  • [35] DECREASED EFFICACY OF LEVODOPA WITH CARBIDOPA IN PARKINSONIAN-PATIENTS AFTER ADRENAL-TO-CAUDATE IMPLANTS
    TSUI, JKC
    PEPPARD, RF
    PETRUK, KC
    ALLEN, G
    BURNS, RS
    CALNE, DB
    NEUROLOGY, 1990, 40 (05) : 845 - 846
  • [36] INITIATION OF LEVODOPA THERAPY IN PARKINSONIAN-PATIENTS SHOULD BE DELAYED UNTIL THE ADVANCED STAGES OF THE DISEASE
    MELAMED, E
    ARCHIVES OF NEUROLOGY, 1986, 43 (04) : 402 - 405
  • [37] DIGITAL ANALYSIS OF THE EFFECTS OF LEVODOPA TREATMENT ON THE VISUAL EVOKED-RESPONSE IN PARKINSONIAN-PATIENTS
    YAAR, I
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1979, 15 (03): : 296 - 296
  • [38] INFLUENCE OF MEAL INGESTION TIME ON PHARMACOKINETICS OF ORALLY-ADMINISTERED LEVODOPA IN PARKINSONIAN-PATIENTS
    BARUZZI, A
    CONTIN, M
    RIVA, R
    PROCACCIANTI, G
    ALBANI, F
    TONELLO, C
    ZONI, E
    MARTINELLI, P
    CLINICAL NEUROPHARMACOLOGY, 1987, 10 (06) : 527 - 537
  • [39] EFFECT OF PERIPHERAL CATECHOL-O-METHYLTRANSFERASE INHIBITION ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF LEVODOPA IN PARKINSONIAN-PATIENTS
    NUTT, JG
    WOODWARD, WR
    BECKNER, RM
    STONE, CK
    BERGGREN, K
    CARTER, JH
    GANCHER, ST
    HAMMERSTAD, JP
    GORDIN, A
    NEUROLOGY, 1994, 44 (05) : 913 - 919
  • [40] CONCENTRATION-EFFECT RELATIONSHIP FOLLOWING LEVODOPA/CARBIDOPA ADMINISTRATION TO ON-OFF PARKINSONIAN-PATIENTS
    ELKOSHI, Z
    CLINICAL NEUROPHARMACOLOGY, 1994, 17 (02) : 147 - 164
12345